Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of astegolimab or UTTR1147A plus standard of care in severe COVID-19 pneumonia
2020-002713-17Phase 2Completed
- Sponsor
- Genentech
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia comparing Astegolimab + standard of care, UTTR1147A + standard of care and Placebo + standard of care (3 arms). Primary endpoint: Clinical status at Day 28. Started Jul 2020; status: completed.
02
Drugs
astegolimabefmarodocokin alfa
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-002713-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002713-17.